Meeting Banner
Abstract #1093

Determination of Tumor Response to Hypoxia-Activated Prodrug TH-302 in Rat Glioma Models

Ashley M Stokes 1 , Charles P Hart 2 , and C. Chad Quarles 1

1 Institute of Imaging Science, Radiology and Radiological Sciences, Vanderbilt University, Nashville, TN, United States, 2 Threshold Pharmaceuticals, California, United States

Tumor hypoxia leads to increased tumor aggressiveness and chemotherapeutic resistance, which has led to the development of hypoxia-activated cytotoxic prodrugs, such as TH-302. As tumor hypoxia is spatially heterogeneous, and thus response to TH-302 is expected to vary spatially, there is a need for imaging-based measures of treatment response. Here, we determined tumor response to TH-302 in two rat glioma models with known differences in tumor hypoxia, and functional diffusion mapping was used to quantify treatment-induced changes in diffusion characteristics that could be indicative of response to hypoxia activated drugs such as TH-302.

This abstract and the presentation materials are available to members only; a login is required.

Join Here